SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 221 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $222,624 | -29.0% | 7,406 | -14.5% | 0.00% | – |
| Q1 2023 | $313,716 | -7.0% | 8,659 | -8.4% | 0.00% | – |
| Q4 2022 | $337,224 | -47.4% | 9,454 | -50.1% | 0.00% | -100.0% |
| Q3 2022 | $641,000 | -5.7% | 18,928 | -19.5% | 0.00% | 0.0% |
| Q2 2022 | $680,000 | -2.7% | 23,519 | +8.7% | 0.00% | 0.0% |
| Q1 2022 | $699,000 | +11.1% | 21,636 | +0.3% | 0.00% | 0.0% |
| Q4 2021 | $629,000 | +18.9% | 21,572 | +8.9% | 0.00% | – |
| Q3 2021 | $529,000 | -6.9% | 19,818 | +7.4% | 0.00% | -100.0% |
| Q2 2021 | $568,000 | +4.2% | 18,448 | -11.4% | 0.00% | 0.0% |
| Q1 2021 | $545,000 | +27.9% | 20,819 | +22.9% | 0.00% | 0.0% |
| Q4 2020 | $426,000 | +29.9% | 16,945 | +7.6% | 0.00% | 0.0% |
| Q3 2020 | $328,000 | -13.0% | 15,753 | -0.8% | 0.00% | 0.0% |
| Q2 2020 | $377,000 | +38.1% | 15,880 | +4.7% | 0.00% | 0.0% |
| Q1 2020 | $273,000 | -26.0% | 15,168 | -2.6% | 0.00% | 0.0% |
| Q4 2019 | $369,000 | -14.4% | 15,571 | -0.6% | 0.00% | 0.0% |
| Q3 2019 | $431,000 | -17.6% | 15,669 | -0.8% | 0.00% | 0.0% |
| Q2 2019 | $523,000 | -39.2% | 15,797 | -35.6% | 0.00% | -50.0% |
| Q1 2019 | $860,000 | -5.5% | 24,544 | -10.4% | 0.00% | 0.0% |
| Q4 2018 | $910,000 | -29.6% | 27,394 | +6.8% | 0.00% | -33.3% |
| Q3 2018 | $1,292,000 | -51.4% | 25,655 | -42.3% | 0.00% | -57.1% |
| Q2 2018 | $2,661,000 | +190.2% | 44,455 | +122.1% | 0.01% | +133.3% |
| Q1 2018 | $917,000 | +8.9% | 20,018 | -5.2% | 0.00% | 0.0% |
| Q4 2017 | $842,000 | -6.2% | 21,127 | -5.9% | 0.00% | 0.0% |
| Q3 2017 | $898,000 | +3.3% | 22,452 | +11.4% | 0.00% | 0.0% |
| Q2 2017 | $869,000 | +40.6% | 20,154 | +1.8% | 0.00% | -25.0% |
| Q1 2017 | $618,000 | -1.6% | 19,790 | -18.3% | 0.00% | -20.0% |
| Q4 2016 | $628,000 | -33.9% | 24,213 | -40.1% | 0.01% | -44.4% |
| Q3 2016 | $950,000 | +5.0% | 40,390 | -3.8% | 0.01% | +12.5% |
| Q2 2016 | $905,000 | -4.3% | 41,975 | -28.3% | 0.01% | +166.7% |
| Q1 2016 | $946,000 | +83.0% | 58,511 | +52.0% | 0.00% | +200.0% |
| Q4 2015 | $517,000 | +20.5% | 38,486 | +34.5% | 0.00% | -50.0% |
| Q3 2015 | $429,000 | – | 28,607 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |